A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension. According to the Food & Drug Administration FDA’s MedWatch:
Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to starting Sprycel, as well as during treatment.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.